Navigation Links
Ranbaxy Gets FDA Approval for Insomnia Drug

Indian drug major Ranbaxy Laboratories Ltd says it has obtained tentative approval from the US Food and Drug Administration to manufacture// and market a drug for insomnia.

The US unit of the company announced Friday that the Office of Generic Drugs, US FDA, has determined the Ranbaxy formulations of Zolpidem Tartrate tablets to be bioequivalent and to have the same therapeutic effect as that of Ambien tablets of Sanofi Aventis US, LLC.

Zolpidem Tartrate tablets are indicated for the short-term treatment of insomnia and related disorders. As per latest data, the total annual market sales for Zolpidem Tartrate tablets were $2.12 billion.

Ranbaxy said the new drug would be manufactured at the company's Ohm Laboratories Inc. facility, based in North Brunswick, New Jersey, USA.

The vice president of sales and marketing of Ranbaxy Pharmaceuticals Inc., USA, Jim Meehan, said that the product would be launched following final approval from the FDA. This would give yet another opportunity for Ranbaxy to expand its product portfolio by offering an affordable generic alternative, he added.

The Jacksonville, Florida-based Ranbaxy Pharmaceuticals Inc. is a wholly owned subsidiary of the company. RPI is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.

Source-IANS
'"/>




Page: 1

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Ranbaxy gets US FDA approval for Lisinopril
3. Ranbaxy Labs Entry Into Anti-Acne Market
4. Ranbaxy trying to make inroads in herbal drugs market
5. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
6. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
7. Ranbaxy opens Drug discovery centre in Gurgaon
8. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
9. SRL Ranbaxy offers quicker bird flu diagnostic test
10. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
11. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
Post Your Comments:
Breaking Medicine Technology:Ascension Orthopedics Hires Key Senior Executives 2FDA Launches Orphan Drug Workshop at KGI 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Twitter Users Can Follow in Real Time as Local Woman Receives Cyberknife Treatment for Lung Cancer 56039 1Twitter Users Can Follow in Real Time as Local Woman Receives Cyberknife Treatment for Lung Cancer 56039 2Twitter Users Can Follow in Real Time as Local Woman Receives Cyberknife Treatment for Lung Cancer 56039 3Twitter Users Can Follow in Real Time as Local Woman Receives Cyberknife Treatment for Lung Cancer 56039 4College Students Get More Drunk When Drinks Are Cheap 56036 1College Students Get More Drunk When Drinks Are Cheap 56036 2Forterus Inc Treatment Centers Showing Consistent Sustainable Growth 3B CEO Paul Howarth Interviewed 56032 1Forterus Inc Treatment Centers Showing Consistent Sustainable Growth 3B CEO Paul Howarth Interviewed 56032 2